Ovid Therapeutics (OVID) announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann joins Ovid from Vigil Neuroscience where she served as Chief Medical Officer
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID:
- Ovid Therapeutics price target raised to $2 from $1.50 at H.C. Wainwright
- Leerink bullish on Ovid Therapeutics, initiates with an Outperform
- Ovid Therapeutics initiated with an Outperform at Leerink
- Ovid Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating
- Ovid Therapeutics Reports Q3 2025 Financial Results